TY - JOUR T1 - Telaprevir triple combination therapy, and dual peginterferon α-2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naïve patients with genotype 1 hepatitis C virus infection JF - Evidence Based Medicine JO - Evid Based Med SP - 143 LP - 144 DO - 10.1136/ebmed-2011-100469 VL - 17 IS - 5 AU - Mark Danta Y1 - 2012/10/01 UR - http://ebm.bmj.com/content/17/5/143.abstract N2 - Commentary on: Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014–24.OpenUrlCrossRefPubMedWeb of Science Until recently, the standard of care for hepatitis C virus (HCV) infection has been pegylated interferon and ribavirin for 48 weeks for genotype 1 and 24 weeks for genotype 3 infection, with overall sustained virological response (SVR), which equates to cure, of 50% and 80%, respectively. With the recent licensing of the protease inhibitors telaprevir and boceprevir, first generation direct acting antivirals (DAAs), we are at the dawn of a new era of HCV therapy. The ILLUMINATE study explores response-guided therapy in HCV treatment naïve individuals using telaprevir in combination with pegylated interferon and ribavirin. ILLUMINATE is a phase 3 non-inferiority study exploring shorter course therapy for HCV infection … ER -